AstraZeneca has completed a $140 million equity investment in Cellectis, a biotech firm at the forefront of gene-editing therapies. This transaction, which follows approval from the French Ministry of Economy, sees AstraZeneca acquiring 10 million Class A and 18 million Class B convertible preferred shares at $5 each.

The Class A shares carry single voting rights, while Class B shares are non-voting, except in dividend distributions. Both share classes are convertible into ordinary shares, with AstraZeneca now holding a 44% share capital and 30% voting rights in Cellectis.

This investment also triggers the board appointments of Marc Dunoyer and Dr. Tyrell Rivers, as decided in Cellectis’ December 2023 shareholder meeting. With no public offering, no prospectus will be issued for this investment.

Cellectis, known for its innovative CAR-T cell therapies and gene-editing in stem cells, continues to advance its mission to address unmet medical needs through its TALEN® technology and PulseAgile electroporation system.

AstraZeneca and Cellectis partner to accelerate development of next-generation therapeutics